The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ikonnikova E.V.

Central State Medical Academy of Administrative Directorate of the President of the Russian Federation;
Institute of Plastic Surgery and Cosmetology

Manturova N.E.

Pirogov Russian National Research Medical University;
Institute of Plastic Surgery and Cosmetology

Kruglova M.S.

School No. 518

Systemic therapy of delayed inflammatory reactions after the introduction of various types of cosmetic fillers. Part 1

Authors:

Ikonnikova E.V., Manturova N.E., Kruglova M.S.

More about the authors

Read: 5683 times


To cite this article:

Ikonnikova EV, Manturova NE, Kruglova MS. Systemic therapy of delayed inflammatory reactions after the introduction of various types of cosmetic fillers. Part 1. Russian Journal of Clinical Dermatology and Venereology. 2021;20(3):85‑91. (In Russ.)
https://doi.org/10.17116/klinderma20212003185

Recommended articles:
Cere­bral protection in transcatheter aortic valve implantation. Piro­gov Russian Journal of Surgery. 2024;(12-2):150-158
Capsular contracture after reco­nstructive plastic surgery for breast cancer. P.A. Herzen Journal of Onco­logy. 2024;(6):78-83
Complications after Laser Treatment. Journal of Venous Diso­rders. 2024;(4):317-327

References:

  1. Humphrey S, Carruthers J, Carruthers A. Clinical experience with 11,460 ml of a 20-mg/ml, smooth, highly cohesive, viscous hyaluronic acid filler. Dermatol Surg. 2015;41:1060-1067. https://doi.org/10.1097/DSS.0000000000000434
  2. Philipp-Dormston WG, Goodman GJ, De Boulle K, Swift A, Delorenzi C, Jones D. Global Approaches to the Prevention and Management of Delayed-onset Adverse Reactions with Hyaluronic Acid-based Fillers. Plast Reconstr Surg Glob Open. 2020;8(4):e2730. https://doi.org/10.1097/GOX.0000000000002730
  3. Sadeghpour M, Quatrano NA, Bonati LM, et al. Delayed-onset nodules to differentially crosslinked hyaluronic acids: comparative incidence and risk assessment. Dermatol Surg. 2019;45:1085-1094. https://doi.org/10.1097/DSS.0000000000001814
  4. Beleznay K, Carruthers JD, Carruthers A, et al. Delayed-onset nodules secondary to a smooth cohesive 20 mg/ml hyaluronic acid filler: cause and management. Dermatol Surg. 2015;41:929-939.  https://doi.org/10.1097/DSS.0000000000000418
  5. Ikonnikova EV, Gensler EM. Problems of injection cosmetology: an overview of complications and methods of their correction. Medical Alphabet. 2020;1:6(420):79-2. (In Russ.). https://doi.org/10.33667/2078-5631-2020-6-79-82
  6. Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013;6:295-316.  https://doi.org/10.2147/CCID.S50546
  7. Alijotas-Reig J, Fernandez-Figueras MT, Puig L. Inflammatory, immunemediated adverse reactions related to soft tissue dermal fillers. Semin Arthritis Rheum. 2013;43:241-258.  https://doi.org/10.1016/j.semarthrit.2013.02.001
  8. Arron ST, Neuhaus IM. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. J Cosmet Dermatol. 2007; 6(3):167-171.  https://doi.org/10.1111/j.1473-2165.2007.00331.x
  9. De Boulle K, Heydenrych I. Patient factors influencing dermal filler complications: prevention, assessment, and treatment. Clin Cosmet Investig Dermatol. 2015;8:205-214.  https://doi.org/10.2147/CCID.S80446
  10. Ikonnikova EV, Manturova NE, Kruglova LS. Delayed inflammatory response to hyaluronic acid fillers in the setting of influenza-like illness. Russian Journal of Skin and Venereal Diseases. 2021;1. (In Russ.).
  11. Monheit GD, Rohrich RJ. The nature of long-term fillers and the risk of complications. Dermatol Surg. 2009;35:1598-1604. https://doi.org/10.1111/j.1524-4725.2009.01336.x
  12. Lemperle G, Nicolau P, Scheiermann N. Is there any evidence for biofilms in dermal fillers? Plast Reconstr Surg. 2011;128:84-85.  https://doi.org/10.1097/prs.0b013e31821ef19b
  13. Snozzi P, van Loghem JAJ. Complication management following rejuvenation procedures with hyaluronic acid fillers-an algorithm-based approach. Plast Reconstr Surg Glob Open. 2018;6:e2061. https://doi.org/10.1097/GOX.0000000000002061
  14. Philipp-Dormston WG, Bergfeld D, Sommer BM, et al. Consensus statement on prevention and management of adverse effects following rejuvenation procedures with hyaluronic acid-based fillers. J Eur Acad Dermatol Venereol. 2017;31:1088-1095. https://doi.org/10.1111/jdv.14295
  15. Cassuto D, Sundaram H. A problem-oriented approach to nodular complications from hyaluronic acid and calcium hydroxylapatite fillers: classification and recommendations for treatment. Plast Reconstr Surg. 2013;132 (4 Suppl 2):48-58.  https://doi.org/10.1097/PRS.0b013e31829e52a7
  16. Alijotas-Reig J, Garcia-Gimenez V. Delayed immune mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long term follow-up and review of the literature. J Eur Acad Dermatol Venereol. 2008;22:150-161.  https://doi.org/10.1111/j.1468-3083.2007.02354.x
  17. Requena C, Izquierdo MJ, Navarro M, Martinez A, Vilalta JJ, Botella R, et al. Adverse reactions to injectable aesthetic microimplants. Am J Dermatopathol. 2001;23:197-202.  https://doi.org/10.1097/00000372-200106000-00006
  18. Sanchez-Carpintero I, Candelas D, Ruiz-Rodrı ́guez R. Dermal fillers: types, indications, and complications. Actas Dermosifiliogr. 2010;101:381-393.  https://doi.org/10.1016/s1578-2190(10)70660-0
  19. Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg. 2009;35:1672-1680. https://doi.org/10.1111/j.1524-4725.2009.01346.x
  20. Requena L, Requena C, Christensen L, Zimmermann US, Kutzner H, Cerroni L. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol. 2011; 64:1-34.  https://doi.org/10.1016/j.jaad.2010.02.064
  21. Lemperle G, Gauthier-Hazan N. Foreign Body Granulomas After All Injectable Dermal Fillers: Part 2. Treatment options. Plast Reconstr Surg. 2009; 123(6):1864-1873. https://doi.org/10.1097/PRS.0b013e3181858f4f
  22. Vidič M, Bartenjev I. An adverse reaction after hyaluronic acid filler application: a case report. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27(3): 165-167.  https://doi.org/10.15570/actaapa.2018.35
  23. Sanchis-Bielsa JM, Bagán JV, Poveda R, Salvador I. Foreign body granulomatous reactions to cosmetic fillers: a clinical study of 15 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(2):237-241.  https://doi.org/10.1016/j.tripleo.2009.03.032
  24. Bitterman-Deutsch O, Kogan L, Nasser F. Delayed Immune Mediated Adverse Effects to Hyaluronic Acid Fillers: Report of Five Cases and Review of the Literature. Dermatol Reports. 2015;7(1):5851. https://doi.org/10.4081/dr.2015.5851
  25. Grass J, Majenka P, Sedlaczek O, Toberer F, Lonsdorf AS. Granulomatous Reaction to Cosmetic Soft Tissue Filler with Late-onset Inflammatory Response. Acta Derm Venereol. 2020;100(15):adv00243. https://doi.org/10.2340/00015555-3601
  26. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239-248.  https://doi.org/10.1111/j.1365-4632.2009.04322.x
  27. Kruglova LS, Yakovlev AB, Shatokhina EA, Surkichin SI, Gryazeva NV, Ivanova II. Pharmacotherapy in dermatology. Part 1. Systemic therapy. Textbook. M.: RIO TSGMA; 2018. (In Russ.).
  28. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 2013; 65(294-298). https://doi.org/10.1002/acr.21796
  29. Clayton SA, Jones SW, Kurowska-Stolarska M, Clark AR. The role of microRNAs in glucocorticoid action. J Biol Chem. 2018;293:1865-1874. https://doi.org/10.1074/jbc.R117.000366
  30. Bledsoe RK. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 2002;110:(93-105). https://doi.org/10.1016/s0092-8674(02)00817-6
  31. Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr. Physiol. 2014;4:965-994.  https://doi.org/10.1002/cphy.c130044
  32. Coutinho AE, Gray M, Brownstein DG, Salter DM, Sawatzky DA, Clay S, et al. 11β-hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology. 2012;153(1):234-240.  https://doi.org/10.1210/en.2011-1398
  33. Hardy RS, Fenton F, Croft AP, Naylor AJ, Begum R, Desanti R, et al. 11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis. J Autoimmun. 2018; 92:104-113.  https://doi.org/10.1016/j.jaut.2018.05.010
  34. Jones IA, Togashi R, Wilson ML, Heckmann N, Vangsness CT Jr. Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol. 2019; 15:77-90.  https://doi.org/10.1038/s41584-018-0123-4
  35. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008; 371:205-214.  https://doi.org/10.1016/S0140-6736(08)60132-4
  36. Caratti G, Iqbal M, Hunter L, Kim D, Wang P, Vonslow RM, et al. REVERBa couples the circadian clock to hepatic glucocorticoid action. J Clin Invest. 2018;128:4454-4471. https://doi.org/10.1172/JCI96138
  37. Oster H, Challet E, Ott V, Arvat E, de Kloet R, Dijk DJ, et al. The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids. Endocr Rev. 2017;38(1):3-45.  https://doi.org/10.1210/er.2015-1080
  38. Grippaudo FR, Girolamo MD, Mattei M, Pucci E, Grippaudo C. Diagnosis and management of dermal filler complications in the perioral region. J Cosmet Laser Ther. 2014;16(5):246-252.  https://doi.org/10.3109/14764172.2014.946048
  39. Turkmani MG, De Boulle K, Philipp-Dormston WG. Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness. Clin Cosmet Investig Dermatol. 2019;12:277-283.  https://doi.org/10.2147/CCID.S198081
  40. Bhojani-Lynch T. Late-onset inflammatory response to hyaluronic acid dermal fillers. Plast Reconstr Surg Glob Open. 2017;5(12):e1532. https://doi.org/10.1097/GOX.0000000000001532
  41. Ikonnikova EV, Kruglova LS. Recurrent inflammatory response after correction of the nasolacrimal sulcus with hyaluronic acid filler: a case report. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2020;19(4):558-562. (In Russ.). https://doi.org/10.17116/klinderma202019041558
  42. Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39:519-548.  https://doi.org/10.1210/er.2018-00097
  43. Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporos Int. 2017;28:3301-3314. https://doi.org/10.1007/s00198-017-4189-7
  44. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517-531.  https://doi.org/10.1016/j.cmet.2010.05.005
  45. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.  https://doi.org/10.1172/JCI2799
  46. Wang R, Jiao H, Zhao J, Wang X, Lin H. Glucocorticoids enhance muscle proteolysis through a myostatin-dependent pathway at the early stage. PLoS One. 2016;11:e0156225. https://doi.org/10.1371/journal.pone.0156225
  47. Lemmey AB, Wilkinson TJ, Perkins CM, Nixon LA, Sheikh F, Jones JG, et al. Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. Eur J Rheumatol. 2018;5:160-164.  https://doi.org/10.5152/eurjrheum.2018.17148
  48. Manolopoulos KN, O’Reilly MW, Bujalska IJ, Tomlinson JW, Arlt W. Acute hypercortisolemia exerts depot-specific effects on abdominal and femoral adipose tissue function. J Clin Endocrinol Metab. 2017;102:1091-1101. https://doi.org/10.1210/jc.2016-3600
  49. Trigolosova IV. Steroid-induced diabetes mellitus. RMZh. 2016;1:54-56. (In Russ.).
  50. Borresen SW, Klose M, Baslund B, Rasmussen AK, Hilsted L, Friis-Hansen L, et al. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. Eur J Endocrinol. 2017;177:287-295.  https://doi.org/10.1530/EJE-17-0251
  51. Newton R, Shah S, Altonsy MO, Gerber AN. Glucocorticoid and cytokine crosstalk: feedback, feedforward, and co-regulatory interactions determine repression or resistance. J Biol Chem. 2017;292:7163-7172. https://doi.org/10.1074/jbc.R117.777318
  52. Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarrés M. Tacrolimus in the treatment of chronic and refractory late-onset immune-mediated adverse effects related to silicone injections. Dermatol Surg. 2012;38(1):38-47.  https://doi.org/10.1111/j.1524-4725.2011.02221.x

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.